[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Alexis Dieter\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100594868",false,"NCT07025044","Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections","Characterizing the Postmenopausal Genitourinary Microbiome in Women Undergoing Onabotulinum Toxin Type A for Overactive Bladder - A Feasibility Trial","MICROAB_Pilot","Inclusion Criteria:\n\n* Natal female \\> 55 years old\n* English-speaking\n* Scheduled to undergo onabotulinum toxin type A for treatment of OAB\n* No menses for \\>1 year if uterus in situ\n* Planning one dose nitrofurantoin for antibiotic prophylaxis at time of onabotulinum toxin type A injection per clinic protocol\n\nExclusion Criteria:\n\n* Diagnosis of painful bladder syndrome\n* Current symptomatic or clinically-suspected UTI within 30 days prior to onabotulinum toxin type A injection procedure\\*\n* Systemic antibiotic exposure within 30 days\\^\n* Prophylactic antibiotic treatment for recurrent UTI within the last 12 months\n* Current systemic immunosuppressive therapy (i.e. prednisone or immunomodulators) immunotherapy, chemotherapy or radiation treatment\n* Prior pelvic radiation\n* Indwelling catheter or intermittent catheterization","FEMALE","55 Years",{"count":19,"type":20},40,"ESTIMATED","OBSERVATIONAL","Single-site prospective observational pilot feasibility study of women with overactive bladder\u002Furge urinary incontinence undergoing onabotulinum toxin type A intradetrusor injections in order to achieve the following objectives:\n\n* Establish a record of successful collaboration with Dr. Ravel, an expert researcher in the female microbiome based at the University of Maryland\n* Demonstrate the investigators' ability to recruit subjects from the diverse population of postmenopausal women undergoing BTX for OAB within MedStar Health Urogynecology clinics\n* Collect, process and analyze urine specimens collected prior to and 4-weeks after BTX injection, and to compare the GU microbiome of self-collected versus clinic-collected samples\n* Assess response to BTX treatment and explore rates of and risk factors for urinary tract infection and incomplete voiding requiring catheterization within the first 4-weeks after BTX",[24,25],"Overactive Bladder (OAB)","Urge Incontinence",[27],"onabotulinum toxin type A","RECRUITING","2025-09-08",{"date":31,"type":32},"2025-09-12","ACTUAL",{"date":34,"type":32},"2025-09-03",{"date":36,"type":20},"2026-06-01",{"name":38,"class":39},"Alexis Dieter","OTHER",""]